RecruitingPhase 1NCT06641908
Metabolic
Gaucher disease type 2
22
studies recruiting now
as of 7 Sept 2026
112
studies registered in total
as of 7 Sept 2026
7
countries with a recruiting site
as of 7 Sept 2026
4 Aug 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 1NCT05544526
CAR T Cells to Target GD2 for DMG
RecruitingPhase 1 / Phase 2NCT07744256
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
RecruitingPhase 1NCT04099797
C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
RecruitingPhase 1 / Phase 2NCT06026657
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 22 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Gaucher disease type 2 study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Gaucher disease type 2
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the gene involved (GBA1).
Treatments being studied
3 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 1/2Sirolimus (Fyarro)
Phase 1/2Methylprednisolone (Medrol)
Phase 1/2Prednisone (Cortan)
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).